A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerRECK, M; KAISER, R; ESCHBACH, C et al.Annals of oncology. 2011, Vol 22, Num 6, pp 1374-1381, issn 0923-7534, 8 p.Article

Blocking lymphotoxin-β receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MadCAM-1) expression and leucocyte margination in chronic DSS-induced colitisSTOPFER, P; OBERMEIER, F; DUNGER, N et al.Clinical and experimental immunology (Print). 2004, Vol 136, Num 1, pp 21-29, issn 0009-9104, 9 p.Article

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsAWADA, A. H; DUMEZ, H; HENDLISZ, A et al.Investigational new drugs. 2013, Vol 31, Num 3, pp 734-741, issn 0167-6997, 8 p.Article

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignanciesDU BOIS, A; HUOBER, J; STOPFER, P et al.Annals of oncology. 2010, Vol 21, Num 2, pp 370-375, issn 0923-7534, 6 p.Article

A phase I dose escalation study off BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursESKENS, F. A. L. M; MOM, C. H; DE VRIES, E. G. E et al.British journal of cancer. 2008, Vol 98, Num 1, pp 80-85, issn 0007-0920, 6 p.Article